RxDoctor Payments Data

Michael Olenginski, DO

Otolaryngology · Kingston, PANPI 1881624856

Payments from drug & device makers

$3,101in general payments, 2019–2025

Across 129 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$569
  • Acclarent, Inc$312
  • GSK$310
  • Optinose US, Inc.$300
  • Aerin Medical Inc.$135
  • plus $454 from 9 others

What the payments were for

  • Food & beverage$2,87293%
  • Education$2297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,101 in reported general payments places this provider in the 70th percentile of 456 otolaryngology providers in Pennsylvania.

See all otolaryngology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,212
Medicare patients
803
Services billed
5,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab28$122,075
Dupixent SyringeDupilumab14$51,157
XhanceFluticasone Propionate12$11,537
Ipratropium Bromide148$4,969
Fluticasone Propionate239$3,174
Mometasone Furoate40$2,537
Flunisolide35$2,293
Ofloxacin46$1,854
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc29$1,595
Azelastine Hcl57$1,553
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort17$1,005
Levocetirizine Dihydrochloride20$457
Meclizine Hcl20$366
Cefdinir11$225
Famotidine12$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$300$11,53712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 456 otolaryngology providers in Pennsylvania.

Other otolaryngology in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →